A Monotherapy Study to Evaluate the Efficacy and Safety of 2 Dose Levels of Albiglutide in Japanese Subjects With Type 2 Diabetes Mellitus (T2DM)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 494 participants.

Also called NCT01733758

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 494 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01733758
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Japan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01733758. Randomized; double masking; primary purpose treatment. Start 2013-02 (registry gives no type); primary completion 2014-06 (actual). Results posted on 2015-05-18.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Monotherapy Study to Evaluate the Efficacy and Safety of 2 Dose Levels of Albiglutide in Japanese Subjects With Type 2 Diabetes Mellitus (T2DM)
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Albiglutide 30 mg weekly
Intervention (Drug)
Albiglutide 50 mg weekly
Intervention (Drug)
Placebo
Intervention (Drug)
Liraglutide 0.9 mg daily
Lead sponsor
GlaxoSmithKline (class: industry)

Record details

Record id
cardio:ct-nct01733758
Content hash
1fccb70c342c6d233a91e15618cf2f0a3191ecc8cb80968fd6c5f38f535def2e